OrbusNeich has announced that its Combo dual therapy stent will be featured in a symposium entitled “Innovation in DES” at the Joint Interventional Meeting (JIM; 14–16 February, Rome, Italy).
At the drug-eluting symposium (chaired by Sigmund Silber, Cardiology Practice and Hospital, Munich, and Corrado Tamburino, chair of the Cardiology Department at Ferrarotto Hospital, Catania, Italy), Alexandre Abizaid, director of the catheterisation laboratory at the Institute Dante Pazzanese of Cardiology in São Paulo, Brazil, and a principal investigator of the ongoing REMEDEE study, will give a presentation entitled “COMBO dual therapy stent: Addressing the limitations of drug-eluting stents.”
“Delayed arterial healing remains a major challenge and predictor of late and very late stent thrombosis after drug eluting stent placement,” said Abizaid. “The concept and design of the COMBO dual therapy stent may address this issue for patients with a high risk of restenosis and potentially reduce our dependence on prolonged dual antiplatelet therapy.”
The symposium will take place at 12:45 p.m. CEST on Thursday, Feb. 14, in Room Giotto.
